United States 113th Congress Status: Died 1 D cosponsors

S 2236 — Strategies to Address Antimicrobial Resistance Act

Last action — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. Died in session

This bill died with 113th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Strategies to Address Antimicrobial Resistance Act - Amends the Public Health Service Act to reauthorize through FY2019 and revise a program to combat antimicrobial resistance. Requires the Secretary of Health and Human Services (HHS) to direct the Assistant Secretary of Health to establish the Antimicrobial Resistance Office. Requires the Secretary to establish the Public Health Antimicrobial Advisory Board to advise the Director of the Office (Director). Requires the Director to update the Public Health Action Plan to Combat Antimicrobial Resistance within one year. Requires the Antimicrobial Resistance Task Force to review, discuss, and further develop the Action Plan. Authorizes the Food and Drug Administration (FDA) to consult with the Director of the Antimicrobial Resistance Office concerning the pending application of any new human or animal antimicrobial drugs. Requires the Public Health Antimicrobial Advisory Board to make recommendations to the Secretary and the Antimicrobial Resistance Office regarding issues such as research priorities and implementation of the Action Plan. Requires the Secretary, acting through the Director of the National Institutes of Health (NIH), to develop an antimicrobial resistance strategic research plan. Gives the Director of the Antimicrobial Resistance Office direct authority over specified antimicrobial resistance activities of the Secretary. Revises demonstration programs to require the Secretary to award grants to promote the uptake and measurement of antimicrobial stewardship programs in health care facilities. Defines "antimicrobial stewardship" to mean coordinated interventions designed to improve and measure the appropriate use of antimicrobial agents. Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) pilot and test health care quality measures to help providers, facilities, and health systems measure and benchmark appropriate antimicrobial use; (2) develop methods to help providers, facilities, and health systems measure and improve antimicrobial use; (3) establish at least 10 Antimicrobial Resistance Surveillance and Laboratory Network sites; (4) work with state health departments to support regional prevention collaboratives designed to interrupt and prevent the transmission of significant antibiotic resistant pathogens being transmitted across health care settings in a geographic region. Requires the Secretary, acting through the Director of the National Institute of Allergy and Infectious Diseases, to establish a Clinical Trials Network on Antibacterial Resistance and a Leadership Group for the Network. Requires the Director of the CDC to: (1) work with various entities to obtain reliable and comparable human antimicrobial drug consumption data by state or metropolitan area, (2) intensify and expand efforts to collect antimicrobial resistance data, (3) report on key trends and major issues related to antimicrobial resistance and use in the United States. Requires the National Coordinator for Health Information Technology to work with the Director of the CDC to determine how best antimicrobial use, susceptibility, and resistance data can be incorporated into meaningful use reports.

Bill Text

We don't have the full text on file for this bill yet.

Read S 2236 on the official United States source →

Action History

  1. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

Advisory bodies Chemical and biological weapons Department of Health and Human Services Executive agency funding and structure Food supply, safety, and labeling Genetics Government information and archives Government studies and investigations Health information and medical records Health promotion and preventive care Infectious and parasitic diseases Medical research Medical tests and diagnostic methods Prescription drugs Research administration and funding Terrorism Veterinary medicine and animal diseases Health care quality Health facilities and institutions Drug therapy Health
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 2236 do?
Strategies to Address Antimicrobial Resistance Act - Amends the Public Health Service Act to reauthorize through FY2019 and revise a program to combat antimicrobial resistance. Requires the Secretary of Health and Human Services (HHS) to direct the Assistant Secretary of Health to establish the Antimicrobial Resistance Office. Requires the Secretary to establish the Public Health Antimicrobial Advisory Board to advise the Director of the Office (Director). Requires the Director to update the Public Health Action Plan to Combat Antimicrobial Resistance within one year. Requires the Antimicrobial Resistance Task Force to review, discuss, and further develop the Action Plan. Authorizes the Food and Drug Administration (FDA) to consult with the Director of the Antimicrobial Resistance Office concerning the pending application of any new human or animal antimicrobial drugs. Requires the Public Health Antimicrobial Advisory Board to make recommendations to the Secretary and the Antimicrobial Resistance Office regarding issues such as research priorities and implementation of the Action Plan. Requires the Secretary, acting through the Director of the National Institutes of Health (NIH), to develop an antimicrobial resistance strategic research plan. Gives the Director of the Antimicrobial Resistance Office direct authority over specified antimicrobial resistance activities of the Secretary. Revises demonstration programs to require the Secretary to award grants to promote the uptake and measurement of antimicrobial stewardship programs in health care facilities. Defines "antimicrobial stewardship" to mean coordinated interventions designed to improve and measure the appropriate use of antimicrobial agents. Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) pilot and test health care quality measures to help providers, facilities, and health systems measure and benchmark appropriate antimicrobial use; (2) develop methods to help providers, facilities, and health systems measure and improve antimicrobial use; (3) establish at least 10 Antimicrobial Resistance Surveillance and Laboratory Network sites; (4) work with state health departments to support regional prevention collaboratives designed to interrupt and prevent the transmission of significant antibiotic resistant pathogens being transmitted across health care settings in a geographic region. Requires the Secretary, acting through the Director of the National Institute of Allergy and Infectious Diseases, to establish a Clinical Trials Network on Antibacterial Resistance and a Leadership Group for the Network. Requires the Director of the CDC to: (1) work with various entities to obtain reliable and comparable human antimicrobial drug consumption data by state or metropolitan area, (2) intensify and expand efforts to collect antimicrobial resistance data, (3) report on key trends and major issues related to antimicrobial resistance and use in the United States. Requires the National Coordinator for Health Information Technology to work with the Director of the CDC to determine how best antimicrobial use, susceptibility, and resistance data can be incorporated into meaningful use reports.
Who sponsors S 2236?
S 2236 is sponsored by Sherrod Brown (D).
What is the current status of S 2236?
This bill died with 113th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track S 2236?
Track S 2236 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 2236

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 2236

Last checked for changes about 8 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →